Financial Statements · Financial Reporting
AS Bravo Pharmaceuticals
Official identifier 14159974Record date 31 Dec 2023
EstoniaReport
- Legal formThe legal or organisational form recorded by the Estonian Business Register. Learn more
- AS
- Report status
- Registered
Dates
- Reporting year
- 2023
- Period start
- 1 Jan 2023
- Submitted date
- 8 Jul 2024
Report
- Consolidated
- No
- Audited
- No
Financial metrics
| Statement | Metric | Value |
|---|---|---|
| Balance sheet | Assets | 299,072 |
| Balance sheet | Cash and cash equivalents | 66 |
| Balance sheet | Current assets | 57,561 |
| Balance sheet | Current liabilities | 186,118 |
| Balance sheet | Equity | 112,954 |
| Balance sheet | Share capital at nominal value | 163,337 |
| Balance sheet | Non-current assets | 241,511 |
| Balance sheet | Non-current liabilities | 0 |
| Balance sheet | Retained earnings (loss) from previous periods | -140,771 |
| Kahjumi katmise ettepanek | Retained earnings (loss) from previous periods | -140,771 |
| Income statement scheme 1 | Depreciation and impairment of non-current assets | -2,835 |
| Income statement scheme 1 | Labour costs | -31,526 |
| Income statement scheme 1 | Revenue | 19,945 |
| Income statement scheme 1 | Annual period profit / loss | -85,212 |
| Income statement scheme 1 | Operating profit (loss) | -85,307 |
| Income statement scheme 1 | Profit (loss) before income tax | -85,212 |
| Note: Labour costs | Employees | 2 |
| Note: Labour costs | Labour costs | 31,526 |
Linked company
Company: AS Bravo Pharmaceuticals